• Mortara
  • Envella Air Fluidized Therapy Bed
  • ORLocate Sponge
  • VisiVest

Spotlight

  • Hill-Rom Holdings, Inc., to Host Fiscal Second Quarter 2017 Earnings Conference Call and Webcast

    CHICAGO, March 20, 2017 - Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal second quarter 2017 earnings conference call and webcast on Friday, April 28, 2017, beginning at 7:30 a.m. (CST) and 8:30 a.m. (ET).

    Hill-Rom Raises Quarterly Dividend Rate; Elects Mary Garrett and Nancy M. Schlichting To Its Board of Directors

    CHICAGO, March 14, 2017 - Hill-Rom Holdings, Inc. (NYSE: HRC) announced today that its board of directors declared a 6 percent increase in the company's quarterly dividend rate, from the previous rate of $0.17 per share to $0.18 per share. The fiscal 2017 quarterly dividend is payable on March 31, 2017, to shareholders of record as of the close of business on March 24, 2017. The indicated annual dividend rate is $0.72 per share.

    Hill-Rom to Present at the Barclays Global Healthcare Conference

    CHICAGO, March 1, 2017 - Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the Barclays Global Healthcare Conference on Wednesday, March 15, 2017, in Miami, Florida. John Greisch, Hill-Rom's president and chief executive officer, is scheduled to present at 2:35 p.m. Eastern Time.

    Hill-Rom to Present at the Cowen and Company 37th Annual Health Care Conference

    CHICAGO, Feb. 21, 2017 - Hill-Rom Holdings, Inc. (NYSE: HRC), announced today that management will present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017, at 4:40 PM EST

    Hill-Rom Completes Acquisition Of Mortara Instrument

    CHICAGO and MILWAUKEE, Feb. 14, 2017 - Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), has completed its acquisition of Mortara Instrument, Inc. (Mortara), for $330 million in cash, primarily financed through a private offering of $300 million of senior unsecured notes. Hill-Rom anticipates the structure of the acquisition will allow the company to qualify for a significant tax benefit, which at a net present value of approximately $40 million reduces the effective purchase price to approximately $290 million.